Evidence supporting the use of: DMSA
For the health condition: Heavy Metal Poisoning
Synopsis
Source of validity: Scientific
Rating (out of 5): 5
Dimercaptosuccinic acid (DMSA) is scientifically validated for the treatment of heavy metal poisoning, particularly for lead, arsenic, and mercury toxicity. DMSA is a water-soluble chelating agent that binds to heavy metals in the bloodstream, forming complexes that are then excreted in the urine. Its efficacy and safety profile have been established in multiple clinical trials and it is approved by the U.S. Food and Drug Administration (FDA) for the treatment of lead poisoning in children and adults. Numerous studies have demonstrated that DMSA effectively lowers blood lead levels and improves symptoms of toxicity. It is also used off-label for mercury and arsenic poisoning, with clinical evidence supporting its benefit in these conditions as well. DMSA is generally preferred over older chelators such as dimercaprol (BAL) and EDTA due to its oral bioavailability, lower toxicity, and fewer side effects. Systematic reviews and toxicology guidelines from organizations such as the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) recommend DMSA as a first-line agent for chelation therapy in lead poisoning. However, it is not recommended for routine use in individuals without documented heavy metal toxicity, as inappropriate use can lead to adverse effects and depletion of essential minerals.